Literature DB >> 34345830

Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients.

Luca Biasco1,2, Natalia Izotova1, Christine Rivat1, Sara Ghorashian3, Rachel Richardson1, Aleks Guvenel1, Rachael Hough4, Robert Wynn5, Bilyana Popova6, Andre Lopes6, Martin Pule7, Adrian J Thrasher1, Persis J Amrolia8,9.   

Abstract

Low-affinity CD19 chimeric antigen receptor (CAR) T cells display enhanced expansion and persistence, enabling fate tracking through integration site analysis. Here we show that integration sites from early (1 month) and late (>3yr) timepoints cluster separately, suggesting different clonal contribution to early responses and prolonged anti-leukemic surveillance. CAR T central and effector memory cells in patients with long-term persistence remained highly polyclonal, whereas diversity dropped rapidly in patients with limited CAR T persistence. Analysis of shared integrants between the CAR T cell product and post-infusion demonstrated that, despite their low frequency, T memory stem cell clones in the product contributed substantially to the circulating CAR T cell pools, during both early expansion and long-term persistence. Our data may help identify patients at risk of early loss of CAR T cells and highlight the critical role of T memory stem cells both in mediating early anti-leukemic responses and in long-term surveillance by CAR T cells.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34345830      PMCID: PMC7611448          DOI: 10.1038/s43018-021-00207-7

Source DB:  PubMed          Journal:  Nat Cancer        ISSN: 2662-1347


  15 in total

1.  CD8+ T Cells Expressing an HLA-DR1 Chimeric Antigen Receptor Target Autoimmune CD4+ T Cells in an Antigen-Specific Manner and Inhibit the Development of Autoimmune Arthritis.

Authors:  Karen B Whittington; Amanda Prislovsky; Jacob Beaty; Lorraine Albritton; Marko Radic; Edward F Rosloniec
Journal:  J Immunol       Date:  2021-11-24       Impact factor: 5.422

Review 2.  Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.

Authors:  Brett A Schroeder; Jennifer Jess; Hari Sankaran; Nirali N Shah
Journal:  Curr Opin Hematol       Date:  2022-07-01       Impact factor: 3.218

Review 3.  Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Authors:  Pei-Hua Lu; Kai-Yan Liu; Xing-Yu Cao; Jing-Jing Li
Journal:  Int J Hematol       Date:  2022-06-23       Impact factor: 2.319

Review 4.  Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.

Authors:  Baixin Ye; Yongxian Hu; Mingming Zhang; He Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

5.  High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion.

Authors:  Carmen Alvarez-Fernández; Javier Briones; Ana Carolina Caballero; Laura Escribà-Garcia; Paula Pujol-Fernández; Eva Escudero-López; Cristina Ujaldón-Miró; Rosanna Montserrat-Torres; Jorge Sierra
Journal:  Cancer Gene Ther       Date:  2022-08-29       Impact factor: 5.854

6.  CAR T cells reach clinical milestone in prostate cancer.

Authors:  Nicholas P Tschernia; Scott M Norberg; James L Gulley
Journal:  Nat Med       Date:  2022-04       Impact factor: 87.241

7.  TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer.

Authors:  Richard E Beatson; Ana C Parente-Pereira; Leena Halim; Domenico Cozzetto; Caroline Hull; Lynsey M Whilding; Olivier Martinez; Chelsea A Taylor; Jana Obajdin; Kim Ngan Luu Hoang; Benjamin Draper; Ayesha Iqbal; Tom Hardiman; Tomasz Zabinski; Francis Man; Rafael T M de Rosales; Jinger Xie; Fred Aswad; Daniela Achkova; Chung-Yang Ricardo Joseph; Sara Ciprut; Antonella Adami; Helge G Roider; Holger Hess-Stumpp; Balázs Győrffy; Jelmar Quist; Anita Grigoriadis; Anette Sommer; Andrew N J Tutt; David M Davies; John Maher
Journal:  Cell Rep Med       Date:  2021-12-21

Review 8.  Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.

Authors:  Melita Irving; Evripidis Lanitis; Denis Migliorini; Zoltán Ivics; Sonia Guedan
Journal:  Hum Gene Ther       Date:  2021-10       Impact factor: 5.695

Review 9.  Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.

Authors:  Pouya Safarzadeh Kozani; Pooria Safarzadeh Kozani; Fatemeh Rahbarizadeh
Journal:  Front Immunol       Date:  2021-10-28       Impact factor: 7.561

10.  Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel.

Authors:  Andreas Peinelt; Melanie Bremm; Hermann Kreyenberg; Claudia Cappel; Julia Banisharif-Dehkordi; Stephanie Erben; Eva Rettinger; Andrea Jarisch; Roland Meisel; Paul-Gerhardt Schlegel; Olaf Beck; Gesine Bug; Jan-Henning Klusmann; Thomas Klingebiel; Sabine Huenecke; Peter Bader
Journal:  Front Immunol       Date:  2022-03-02       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.